-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

Benzinga·08/13/2026 14:43:11
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.